Xeris Biopharma Holdings Inc. buy Barclays PLC
Start price
08.12.25
/
50%
€6.01
Target price
08.12.26
-
Performance (%)
-13.87%
Price
15.04.26
€5.25
Summary
This prediction is currently active. The prediction for Xeris Biopharma Holdings Inc. disappoints with a performance of -13.87%. This prediction currently runs until 08.12.26. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Xeris Biopharma Holdings Inc. | 0.768% | 0.768% |
| iShares Core DAX® | 0.444% | 3.030% |
| iShares Nasdaq 100 | 3.819% | 4.073% |
| iShares Nikkei 225® | 1.148% | 6.904% |
| iShares S&P 500 | 2.371% | 2.677% |
Comments by Barclays_PLC for this prediction
In the thread Xeris Biopharma Holdings Inc. diskutieren
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Ratings data for XERS provided by MarketBeat